1 May 2018
Noted experts look back at key advancements that have shaped the field and JAD’s role in the progress that has been achieved
Amsterdam, NL – IOS Press is pleased to announce that 2018 marks the 20th anniversary of the Journal of Alzheimer’s Disease (JAD). One of the many events celebrating this milestone is the publication of an open access issue (JAD 62:3) looking back at 20 years of Alzheimer’s disease (AD) research, which is now available online.
JAD has had a significant impact on the advancement of AD research over the last 20 years, and the translation of that research into clinical practice. Since its launch in 1998, It has published more papers on AD than any other peer-reviewed journal and received more citations than any other AD-focused journal. It has embraced publication of emerging and sometimes controversial lines of research, many of which later gained wide acceptance.
This special issue, co-edited by George Perry, PhD, Jesús Avila, MD, Massimo Tabaton, MD, and Xiongwei Zhu, PhD, features 35 specially commissioned review articles detailing 20 years of ground-breaking AD research, plus personal perspectives from key researchers in the field.
JAD’s Editor-in-Chief George Perry, PhD, Dean of the College of Sciences and Professor of Biology at the University of Texas at San Antonio, recalls the early days of the journal: “The plan was to design a journal that reflected the field through creating community. Our guiding principles were, and continue to be, a robust editorial structure guided by an outstanding group of international experts, openness to novel topics, reviewer selection, scientometric analysis, awards programs, and historical compendia. These are all focused on building a JAD community.”
JAD is dedicated to advancing understanding of the physiological mechanisms underlying the disease and its prevention and treatment. The authoritative reviews in this special issue chronicle important breakthroughs and present the state of the art on significant topics including aging without dementia, biomarkers, genetics and epigenetics, amyloid peptides, tau proteins, mitochondria and mitochondrial cascades, oxidative stress, oligomers and inflammation, metals, AD as type 3 diabetes, the angiotensin hypothesis in AD, neuroimaging, translational medicine, emerging treatment options (successes and failures), immunotherapy, and optimized care.
The issue features two personal perspectives. Isidro Ferrer, MD, PhD, writing in “Sisyphus in Neverland,” provides a broad-ranging, historical perspective comparing AD research to the pursuit and enjoyment of art. In it we are reminded that “the feeling of beauty may also occur in science.”
“While I still Remember: 30 Years of Alzheimer’s Disease Research,” by Thomas B. Shea, PhD, is a career-spanning perspective that recounts how he transitioned from basic to clinical, and moved from bench to bedside and back again. It includes “some of the more humorous and poignant twists along the way that some older players may find familiar, and I hope might inspire some younger players to hang in there.”
“We celebrate and thank our community for supporting 20 years of JAD’s vision of advancing novel approaches to understanding Alzheimer’s disease,” commented Dr. Perry. “JAD’s community is well positioned to lead, in the next 20 years, the innovation essential to discover effective therapeutics for Alzheimer’s disease.”
# # #
NOTES FOR EDITORS
Journal of Alzheimer’s Disease, Volume 62, Issue 3 (2018)
Edited by George Perry, PhD, Jesús Avila, MD, Massimo Tabaton, MD, and Xiongwei Zhu, PhD
View the Complete Table of Contents. All articles are openly available.
Contacts:
George Perry, PhD
Editor-in-Chief, Journal of Alzheimer's Disease
Dean and Professor of Biology, The University of Texas at San Antonio
+1 210 458 4450
george.perry@utsa.edu
Carmel McNamara, PhD
IOS Press
+31 20 688 3355
c.mcnamara@iospress.nl
ABOUT THE JOURNAL OF ALZHEIMER’S DISEASE (JAD)
Celebrating its 20th anniversary in 2018, the Journal of Alzheimer's Disease (http://www.j-alz.com) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment, and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease, and clinical trial outcomes. The Journal of Alzheimer's Disease has an Impact Factor of 3.731 according to Clarivate Analytics’ 2016 Journal Citation Reports®. JAD is published by IOS Press.
ABOUT IOS PRESS
IOS Press (www.iospress.com) is headquartered in Amsterdam with satellite offices in the USA, Germany, India and China and serves the information needs of scientific and medical communities worldwide. IOS Press now publishes over 100 international journals and about 75 book titles each year on subjects ranging from computer sciences and mathematics to medicine and the natural sciences.
